Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 3:6:59-68.
doi: 10.2147/vhrm.s5217.

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A

Hans-Christoph Rossbach  1
Affiliations
Review

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A

Hans-Christoph Rossbach. Vasc Health Risk Manag. .

Abstract

Individuals with severe factor VIII deficiency experience recurrent hemorrhages and develop progressive joint damage. Large retrospective, nonrandomized studies of patient cohorts followed over decades show that factor prophylaxis initiated at an early age before the onset of recurrent bleeding reduces the incidence of hemophilic arthropathy. Two recent prospective, multicenter, randomized trials conducted in Europe (the ESPRIT study) and the USA (the Joint Outcome Study) confirm the efficacy of prophylaxis in the prevention of hemarthroses and arthropathy. Regular prophylaxis initiated in early childhood enhances the quality of life for patients with severe hemophilia and reduces the risk of inhibitor development. The substantial costs of such preventative therapy may be offset by the reduced expenditures that the care of degenerative joint disease in adult hemophilia patients would otherwise require.

Keywords: arthropathy; bleeding; factor VIII; hemophilia; prophylaxis.

PubMed Disclaimer

References

    1. Rosner F. Hemophilia in classic Rabbinic texts. J Hist Med Allied Sci. 1994;49:240–250. - PubMed
    1. Patek AJ. Hemophilia II: Some properties of a substance obtained from normal plasma effective in accelerating the clotting of hemophilic blood. J Clin Invest. 1937;16:113–124. - PMC - PubMed
    1. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost. 2003;29:23–30. - PubMed
    1. Ikkala E, Heilske T, Myllyla G, et al. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930–1979. Br J Haematol. 1982;52:7–12. - PubMed
    1. Chorba TL, Holman RC, Strine TW, et al. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol. 1994;45:112–121. - PubMed